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The yeast two-hybrid system was used to isolate and characterize protein interactors of the 
N-terminal domain of the serine protease Omi/HtrA2 (high temperature requirement protein 
A2) encompassing amino acids 31-133. This large domain of Omi/HtrA2 is usually cleaved and 
removed through autoproteolysis to produce the mature form of the protein. Whether the N-
terminal domain has any function after its removal is unknown. Omi/HtrA2 is involved in a variety 
of diseases including cancers, neurodegenerative disorders, and metabolic disorders, but thus far, 
it is assumed that its normal function is the degradation of specific substrates. To characterize 
any potential function of Omi/HtrA2’s unique amino terminus, specific interactors were isolated. 
One such interactor was the small GTPase Rab2A protein. We discuss the implications of this 
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CHAPTER 1: INTRODUCTION AND REVIEW OF LITERATURE 
Structure 
Omi/HtrA2 (high temperature requirement protein A2) is an ATP-independent serine 
protease primarily localized in the mitochondrial intermembrane space, although it has also been 
identified in both the endoplasmic reticulum and the nucleus [1-4]. Within mitochondria, Omi 
plays key roles in maintenance of mitochondrial homeostasis and thus has been described as 
performing a pro-survival function [1, 5, 6]. However, in response to stress, Omi translocates to 
the cytosol, where it induces cellular apoptosis [2]. Omi was originally identified through a yeast 
two-hybrid screen for protein interactors of Mxi2, an alternatively spliced form of the p38 stress 
kinase [2]. It was later independently discovered through a yeast two-hybrid screen for protein 
interactors of presenilin-1, a protein linked to Alzheimer’s disease [1]. 
Encoded by a gene found on human chromosome 2p12, Omi is a 458 amino acid protein 
of molecular weight 49 kDa that is expressed ubiquitously [2, 3]. Omi belongs to a family of 
proteins known as high temperature requirement A proteins (HtrA) and shows homology to 
bacterial HtrAs, a class of proteins with dual chaperone and peptidase function that varies 
according to the temperature [1]. Among mammals, the sequence for Omi has been found to be 
highly conserved and constitutes one of four HtrA proteases that have been identified, along with 
HtrA1, HtrA3, and HtrA4. Omi is unique within the mammalian HtrAs because it is mitochondrial 
while its paralogs are secreted [1]. 
The sequence of Omi consists of a mitochondrial targeting signal, transmembrane domain, 
a proteolytic trypsin like domain (including the catalytic triad of amino acids essential for its serine 
protease function), and a PDZ domain (Figure 1) [16]. X-ray crystallography has revealed that 
 2 
Omi consists of seven -helices and five -sheets [16]. In its active form, Omi exhibits a 
homotrimeric structure with a pyramid shape: the IAP domain is located at the top of the pyramid 
while the PDZ domain forms the base of the pyramid. This PDZ domain restricts access to the 
active site and therefore regulates the activity Omi’s serine protease domain [16]. Trimerization is 
crucial for Omi to function as mutation of a highly conserved phenylalanine 149 residue necessary 
for trimerization has been shown to abolish Omi’s serine protease function [16, 29]. In its inactive 
form in the IMS of the mitochondria, Omi’s transmembrane domain has been postulated to anchor 
the protein to the inner mitochondrial membrane. Omi is also found in its soluble active form 
within the IMS [18].   
 Alignment between the full length amino acid sequence of mouse and human Omi revealed 
that the mature form of the protein (amino acids 134-458) shows a high degree of similarity with 
about 95% of residues identical. However, the N-terminal domain has lower levels of similarity 
with only 61% of residues conserved (Figure 2). Within the N-terminal domain, the sequence for 
the transmembrane domain and mitochondrial targeting signal are similar, but the majority of the 
differences are located in the linker region between the targeting signal and transmembrane 
domain. Human Omi possesses a thrice repeated PRAXXTXXTP motif within the linker region 
that is completely absent from mice. Alignment performed between the first 133 amino acids of 
Omi across various species including humans, mice, rats, cows, chimpanzees, and guinea pigs 
suggested that this PRAXXTXXTP motif is only found in primates (Figure 3). The function of 
this PRAXXTXXTP motif is unknown, but when Omi is expressed in Escherichia coli cells, the 
PRAXXTXXTP motif was shown to cause human Omi to be much more susceptible to proteolytic 
degradation compared to mouse Omi [43]. 
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Even though mitochondria contain their own genome, the proteins encoded by these genes 
are limited and mainly include subunits of the respiratory chain as well as ATP synthase. 
Therefore, the vast majority of mitochondrial proteins are nuclear encoded and after being 
synthesized on cytosolic ribosomes, must be targeted to mitochondria. This post-translational 
import usually occurs through an N-terminal signal sequence [32]. While the specific sequence of 
these targeting signals is not highly conserved among mitochondrial proteins, certain 
characteristics have been shown to be conserved including length (20-60 AA), charge (net 
positive), and the presence of stabilizing N-terminal residues in the mature protein [42]. 
Comparative analysis of the mitochondrial N-termini of various proteins from mice, humans, and 
yeast has revealed that Omi is unique in that its N-terminal pre-sequence is abnormally long at 133 
amino acids [33]. This deviation serves as further impetus for investigating the potential fate of 
















Figure 1. Structure of Omi 
Omi is a 458 amino acid serine protease that consists of a large mitochondrial targeting signal, transmembrane domain, 
proteolytic trypsin-like domain, and a PDZ domain (including a conserved AVPS motif crucial for interactions with 
IAPs as well as the catalytic triad of amino acids). In its active form, Omi forms a homotrimeric pyramid structure 
with its IAP-binding domain (IBD) at the top and its PDZ domain at the base. The PDZ domain controls substrate 











Figure 2. Alignment of the full length amino acid sequences of Omi/HtrA2 in Homo sapiens and Mus 
musculus 
This alignment was performed using Clustal Omega with the numbers referring to the position of the amino acid 
residues. The functional domains present in both species include: a mitochondrial targeting signal (aa 1-40) indicated 
in blue font, a transmembrane domain (aa 105-125) boxed in purple, the PDZ domain (aa 364-445) in orange font, 
and the catalytic triad (histidine 198, aspartate 228, and serine 306) in blue underlined font that is boxed in green. The 
PRAAXXTXXP motif is indicated in red. An asterisk (*) indicates identical residues, a colon (:) indicates residues 









Figure 3. Alignment of the N-terminal amino acid sequence of Omi/HtrA2 across numerous species 
 This alignment was performed using Clustal Omega and compares the first 133 amino acids of HtrA2 in Homo sapiens 
(human), Mus musculus (mouse), Rattus norvegicus (rat), Bos taurus (cow), Cavia procellus (guinea pig), and Pan 
troglodytes (chimpanzee). The numbers refer to the position of the amino acid residues. The functional domains 
present include: a mitochondrial targeting signal (aa 1-40) indicated in blue font and the transmembrane domain (aa 
105-125) boxed in purple. The PRAAXXTXXP motif is indicated in red. An asterisk (*) indicates identical residues, 







Omi plays dual roles in maintaining mitochondria homeostasis under normal conditions 
and promoting cell death under conditions of stress. Omi triggers cell death through two different 
pathways: caspase dependent cell death through interactions with inhibitors of apoptosis proteins 
(IAP) or caspase independent cell death through usage of its serine protease domain [17]. To 
induce caspase dependent cell death, Omi functions in a similar manner to proteins such as 
Smac/DIABLO, Grim, Reaper, and HID. These proteins are released from mitochondria to the 
cytosol following stress, and once in the cytosol, are able to bind to the BIR (baculovirus IAP 
repeat) domain of IAPs to deter their function and trigger activation of caspases that bring about 
cell death [19, 20]. In response to an apoptotic signal, Omi is processed into its active form through 
cleavage of its first 133 amino acids to produce the processed protein, which reveals the AVPS 
motif on its N-terminal domain essential for recognition and binding of the BIR or IAPs [19]. The 
importance of this motif has been verified in studies that observed that Omi’s ability to induce cell 
death is drastically reduced by mutations within its AVPS motif or its serine protease domain, and 
its apoptotic function is altogether halted by mutations to both the AVPS motif and proteolytic 
domain [19]. Omi has also been observed to cause apoptosis through interactions with proteins 
outside of IAPs, such as ped/pea15 and HAX-1 [21, 22]. The serine protease activity of Omi, and 





























Figure 4. Programmed cell death via mitochondria 
The release of pro-apoptotic proteins from the mitochondria into the cytosol induces cell death. One pathway through 
which this occurs involves the release of Smac/DIABLO and Omi/HtrA2, two mitochondrial intermembrane space 
proteins that antagonize IAPs. This leads to activation of caspase-3 and apoptosis. Omi/HtrA2 has also been postulated 









As mentioned previously, Omi also plays a key pro-survival function within the 
mitochondria. Increased mitophagy is observed for cells lacking functional Omi, due to Omi’s role 
in regulating levels of the mitochondrial E3 ubiquitin ligase Mulan. Accumulation of the Mulan 
causes a concomitant decrease in mitofusion 2 (a protein which promotes mitochondrial fusion), 
leading to the observed mitophagy [19]. Furthermore, Omi has been suggested to play a key role 
in mitochondrial protein quality control and maintenance of mitochondrial homeostasis. Omi aids 
in the elimination of excessive or misfolded proteins within the mitochondrial intermembrane 
space [24]. The absence of Omi results in elevated levels of the mitochondrial proteins Lon 
protease 1 and prohibitin, leading to decreased mitochondrial membrane potential, the generation 
of reactive oxygen species, and a decrease in ATP production [28]. 
Omi’s protective function is also clear through the Parkinsonian phenotype exhibited by 
mnd2 mice that possess nonfunctional Omi through the homozygous mutation Ser276Cys. This 
mutation in Omi was postulated to limit substrate access to the active site of Omi, as deletion of 
the PDZ restores partial function [7]. Introduction of a human Omi transgene into the neuronal 
tissues of mnd2 mice prevented development of the Parkinsonian phenotype, but the mice instead 
exhibited hallmark signs of premature aging including weight loss, hair loss, curved spine, and 
enlarged hearts [6]. Furthermore, overexpression of Omi in the neuronal cells of transgenic mice 
revealed a normal phenotype rather than increased signs of apoptosis, leading to the conclusion 





Implications for Disease 
  Non-functional Omi has been implicated in a variety of neurodegenerative disorders 
including Parkinson’s disease (PD), Alzheimer’s disease (AD), and Huntington’s disease (HD). 
Mnd2 (motor neuron degeneration 2) mice possessing a homozygous mutation for Ser276Cys 
within Omi’s proteolytic domain showed hallmark symptoms generally observed in PD including 
loss of neurons in the striatum of the basal ganglia, reduced body weight, reduced organ size, and 
muscle wasting before an early death (Figure 5) [7]. These mice exhibited increased vulnerability 
to stressed-induced permeabilization of the mitochondrial membrane that leads to cellular 
apoptosis [17]. Phosphorylation of Omi has also been suggested to be important to the functioning 
of its protease domain as mutations of the mitochondrial enzyme PTEN-induced putative kinase-
1 (PINK1), which has been implicated in early onset AD, resulted in lower levels of 
phosphorylation of Omi near a site of mutation in human patients with PD [8]. 
This link between mutations affecting Omi’s proteolytic activity and PD has been 
corroborated by screenings performed on German PD patients, which revealed high proportions 
of patients with the G399S (located in the PDZ domain) or A141S (located in the N-terminus of 
mature Omi) missense mutation compared to the general population [9]. Another study performed 
with Belgian PD patients showed that a R404W mutation (located in the PDZ domain) as well as 
variations in 5’ and 3’ regulatory regions that affect Omi expression increase susceptibility to PD 
[27].  However, the veracity of these findings is yet to be confirmed, as another group examining 
a cohort of North American patients found equal proportions of these mutations within a control 
group compared to a group afflicted with young and late onset PD [10].  
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Omi has also been suggested to be involved in various types of cancers. Gastric mucosal 
cells were found to have reduced expression of Omi compared to non-cancerous stomach cells, 
leading to the conclusion that perhaps a drop in Omi’s apoptotic activity resulted in cancer 
development [13]. Researchers have also identified potential links between Omi expression and 
resistance to treatment with the alkylating agent cisplatin in ovarian cancer since cisplatin’s 
mechanism of action involves increasing levels of Omi to promote apoptosis in cancerous cells 
and cisplatin resistant cancer cells had markedly lower levels of cytosolic Omi [14]. Conversely, 
Omi was found to be highly expressed in prostate cancer cells compared to both normal patients 
and those with benign prostate hyperplasia, leading researchers to conclude Omi contributes to 
prostate cancer development [15]. Because of the variability of gene expression observed among 
the various types of cancers, it is difficult to draw a definitive conclusion on the role of Omi in the 
development and progression of cancer. Nonetheless, Omi’s vital role in balancing cell death and 
homeostasis suggests a high likelihood that aberrant expression of Omi could disturb this balance 
and trigger cancer.   
Whole exome sequencing (WES) has led to identification of recessive mutations in Omi 
that cause 3-methylglutaconic aciduria (3-MGA-uria), a marker of metabolic dysfunction in which 
excessive amounts of 3-methylglutaconic acid are excreted. A study of four human patients lacking 
Omi due to a splicing mutation and a five base pair deletion observed increased susceptibility to 
apoptosis, abnormal cristae structure, and neurodegeneration in addition to 3-MGA-uria [30]. 
Similarly, another study using WES on five patients that presented with 3-MGA-uria noted 
recessive variants of Omi that caused seizures, hypotonia, neutropenia, and cardio-respiratory 
problems [31]. Both studies noted no abnormalities in mitochondrial network morphology or 
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deviations in the mitochondrial respiratory chain, although abnormal levels OPA1, a protein 
important in balancing fusion and fission in mitochondria, were observed [30, 31]. 
Thus, Omi has been implicated in a variety of diseases including cancers, 
neurodegenerative disorders, and metabolic disorders. Additional insight into Omi’s mechanism 
of function through identification of protein interactors of its N-terminal domain could provide 
information about the pathways that result in disease phenotypes as well as possible methods to 





























Figure 5. Phenotype of Mnd2 mice 
Mnd2 mice with a homozygous mutation within Omi’s catalytic domain exhibit neurological symptoms at 20 days 












CHAPTER 2: MATERIALS AND METHODS 
Yeast Two-Hybrid Overview 
The yeast two-hybrid screen was performed using the EGY48 yeast strain containing the 
pSH 18-34 reporter construct, which includes the LacZ gene for β-galactosidase under the control 
of LexA operators. These yeast also contain an endogenous leucine gene under the control of LexA 
operators. The protein of interest (Omi31-133), termed the “bait,” was fused to the LexA DNA 
binding protein through the use of the pGilda vector. The pGilda vector contained a HIS3 
selectable marker as well as a GAL1 promoter, which is repressed by glucose and induced by 
galactose. The potential interactors from the HeLa cDNA library, termed the “prey,” were fused 
to the B42 transcriptional activator through the use of the pJG4-5 vector, which contains a GAL1 
promoter as well as a TRP1 selectable marker. Interaction between the bait and prey resulted in an 
active transcription factor that allowed for expression of two reporter genes. A positive interaction 
was indicated by yeast that was able to survive in media lacking leucine as well as produced a 
characteristic blue color in the presence of X-Gal.  
 Before performing the screen, a color and growth test were used to confirm that the two 
reporter genes could not be activated without interaction between the bait and prey. For the growth 
test, yeast that had been transformed with the pGilda vector containing Omi31-133 was grown 
overnight in U-H- glucose media and then transformed with the empty pJG4-5 vector. Varying 
dilutions were grown on U-H-W-L- Galactose/Raffinose plates. The inability of the yeast to grow 
on medium lacking leucine confirmed that without interaction of the bait and prey, the gene for 
leucine was not activated. For the color test, yeast was streaked on U-H-W- glucose plates and 
incubated for a few days. Colonies from this transformation were plated on U-H-W- 
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Galactose/Raffinose/X-Gal plates. The absence of blue colonies indicated that the bait protein did 


























Figure 6. The Yeast Two-Hybrid System 
Interaction between the LexA-Omi31-133 bait (fused to the binding domain) and the unknown prey protein from the 
HeLa cDNA library (fused to the activating domain) results in formation of an active transcription factor that binds to 
the LexA promoter. This results in the expression of the endogenous LEU2 gene as well as the LacZ gene to form β-
galactosidase and leucine. On a plate with X-Gal, positive interactors form blue colonies. DNA sequencing allows for 









Polymerase Chain Reaction 
The target DNA sequence corresponding to amino acids 31-133 of the N-terminal domain 
of Omi was amplified through PCR. The primers used in the PCR reaction and included restriction 
sites for EcoRI and BamHI (Table 1). For the PCR reaction, the following mixture was used: 20 
ng of template DNA, 10 nM in 1 µL of each of the primers, 5 µL of 10X PCR Buffer containing 
Mg2+, 1.5 units in 1 µL of Taq polymerase, 10 µM of dNTPs, and sterile water to bring the solution 
to a final volume of 50 µL. The PCR program used was: denaturation for 2 minutes at 96oC 
followed by 25 cycles of denaturation for 30 seconds at 96oC, annealing for 30 seconds at 62oC, 
and elongation for 30 seconds at 72oC. The samples were then subjected to a final elongation for 




















Table 1. Primer Sequences for Omi31-133. 
Primer  Sequence (5  3) Restriction Site 
Forward GGCGAATTCTTGACCCCTGACCTCCGGG  EcoRI 
Reverse CGCGGATCCTTAGGCGAGGACGGCCGGAG  BamHI 
 
These forward and reverse primers were used to amplify the cDNA sequence for Omi31-133 with an EcoRI restriction 










DNA Precipitation  
1/10 sample volume of 3M sodium acetate pH 5.5 and 2 sample volumes of 100% ethanol 
kept at-20 oC were added to the DNA solution. This sample was mixed and then stored at -20 oC 
for at least 20 minutes. The sample were then centrifuged at 13,000RPM at 4 oC for 20 minutes. 
The supernatant was discarded. 250 µL of 70% ethanol was added to the pellet to wash away 
residual salt. The sample was centrifuged again at 13,000RPM for 5 minutes at 4 oC. The 
supernatant was discarded. The pellet was then dried for five minutes in a speed vacuum. The dried 
pellet was re-suspended in 50 µL of sterile water.  
Restriction Enzyme Digestion  
Both the vector and DNA insert were digested with BamHI and EcoRI in preparation for 
ligation. The restriction enzyme mixture included: 50 µL of DNA, 37 µL of sterile water, 10 µL 
of 10X Restriction Enzyme Buffer, 1.5 µL BSA, and 1.5 µL of the restriction enzyme EcoRI at 10 
units/µL. This mixture was incubated at 37oC. At the end of an hour, an additional 0.5 µL of EcoRI 
was added. The mixture was left in the water bath for an additional hour for a total of two hours. 
Following the two hours, the DNA was precipitated from the solution and the digestion was 
repeated with the restriction enzyme BamHI. DNA gel electrophoresis was performed to determine 
whether the digestion was successful and to estimate the DNA concentration in the vector and 
insert solutions.  
DNA Gel Electrophoresis  
A 1.5% agarose gel was used to determine the size and concentration of the DNA present 
in each sample. This gel was created by mixing 100 µL of 1X TAE (0.04 M Tris-acetate, 0.001 M 
EDTA) with 1.5 g of agarose powder. This solution was microwaved for approximately 90-120 
seconds until the agarose was observed to have completely dissolved. The solution was then cooled 
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under running cold water and 0.5 µg/µL ethidium bromide was added and mixed by swirling. The 
solution was poured into a gel tray with well combs and left to solidify at room temperature. 2-5 
µL of each sample of DNA was mixed with 5 µL of 10X Loading Buffer (30% glycerol, 2% 
Orange-G in 1X TAE) and loaded into the wells of the gel. A GeneRuler 1 kb DNA ladder was 
run along with the samples. The gel was covered with 1X TAE Buffer and run at 150V until the 
dye had migrated an appropriate distance in the gel. The gel was visualized using ultraviolet light 
in a Biorad Gel-Doc machine.  
DNA Ligation 
To determine the amount of vector and insert to use, gel electrophoresis was used to 
visualize and estimate the concentration of DNA in the insert and vector solutions. The amount of 
DNA used in the ligation should be roughly in a 3:1 insert to vector ratio. The reaction mixture 
included 1.5 µL of Ligation Buffer, 1.5 µL of ATP, 1 µL DNA ligase, 1.5 µL of 10X buffer, and 
varying amounts of insert and vector. A final volume of 15 µL was achieved by addition of sterile 
water to bring up the volume of the reaction mixture. The samples were incubated at room 
temperature for 20 minutes and at 72oC for 15 minutes in a heating block. The samples were stored 
at 4oC.  
Bacterial Transformation 
Approximately 3-4 µL of the DNA ligation was added into a 100 µL aliquot of competent 
DH5α bacterial cells and transferred to an electroporation cuvette cooled to 4 oC. The cuvette was 
placed in the Bio-Rad Gene Pulser to deliver a single exponential decay pulse of 2.5 kV at 400Ω. 
900 µl of room temperature LB medium was immediately added to the cuvette, which was gently 
mixed and transferred to a microcentrifuge tube. This tube was incubated at 37 oC for one hour 
 21 
while spinning. Various volumes of the cells were plated on LB agar plates containing ampicillin 
and incubated overnight at 37 oC.  
Isolation of Plasmid DNA from Bacteria (Boiling Method) 
Individual colonies were isolated from the LB AMP plates and grown in 1.5 mL of LB 
AMP media overnight while shaking at 37 oC. The following day, the suspensions were poured 
into 1.5 mL microcentrifuge tubes and spun at 13,000 RPM for 2 minutes. The supernatant was 
aspirated and the pellet was resuspended in 300 µL of a STET/Lysozyme solution (8% sucrose, 
5% 100X Triton, 50 mM of Tris-HCl pH 8, 50 mM of EDTA, 10 mg/mL of lysozyme). These 
samples were placed in a boiling water bath for 1 minute and centrifuged at 13,000RPM for 10 
minutes. The pellet with cellular debris was removed with a toothpick and 200 µL isopropanol was 
added to the supernatant. The samples were inverted and mixed before centrifuging at 13000 RPM 
for 10 minutes. The supernatant was discarded and 300 µL of 70% ethanol was added to wash the 
pellet. This solution was centrifuged for 5 minutes at 13,000 RPM. The supernatant was discarded 
and the DNA pellet was dried in a speed vacuum for 10 minutes. The resulting dried pellet was 
resuspended in 50 µL of TE.  
Isolation of Plasmid DNA from Bacteria (Clean Miniprep - QIAPrep) 
The QIAprep Spin Miniprep Kit was used to isolate plasmid DNA from bacteria that had 
been incubated with shaking overnight at 37oC in 1.5 mL of LB AMP media. These suspensions 
were transferred to microcentrifuge tubes and centrifuged at 13,000 RPM for 2 minutes at room 
temperature. The supernatant was aspirated and the pellet was resuspended in 200 µL of 
Resuspension Buffer P1 with RNase A (100 µg/mL). 200 µL of Lysis Buffer P2 was added, and 
the tubes were gently inverted several times until a homogeneously colored suspension was 
obtained. Next, 300 μL of Neutralization Buffer N3 was added and the tubes were once again 
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inverted several times until the solution appeared cloudy. The suspensions were centrifuged at 
13,000 RPM for 10 minutes and the supernatant was transferred by pipette to a QIAprep spin 
column with a 2 mL collection tube. These columns were centrifuged for 1 minute at 13,000 RPM 
and the flow-through in the collection tube was discarded. The columns were then washed with 
500 µL of PB Buffer and centrifuged for an additional 1 minute at 13,000 RPM to remove any 
remaining wash buffer that might inhibit enzymatic reactions performed later on. The flow through 
was discarded once again followed by another centrifugation step for 1 minute at 1,3000 RPM. 
The spin columns were then transferred to a 1.5 mL clean microcentrifuge tube and 50 µL of EB 
Buffer (10 mM Tris-HCl, pH 8.5) was added to the center of the column. This was allowed to sit 
for a minute before centrifuging for 1 minute at 13,000 RPM to elute the DNA.  
Yeast Transformation 
A single colony was inoculated in 50 mL of medium and grown overnight shaking at 30°C. 
The following day, the suspensions were centrifuged at 3800 RPM for 5 minutes and the 
supernatant was discarded. The cells were then washed with 10 ml TE pH 7.5 (10mM Tris pH 5, 
1 mM EDTA pH 8) before being centrifuged once again at 3800 RPM for 5 minutes. The cells 
were resuspended in 5 mL LA (0.1 M LiAC in TE) and incubated in a shaker for 2 hours at 30°C. 
The cells were centrifuged at 3800 RPM for 5 minutes and the supernatant was discarded. The 
cells were once again resuspended in 5 mL of LA. 300 µL of this solution was aliquoted into 
microcentrifuge tubes to which 1 µL of denatured salmon sperm DNA and 1 µg of DNA was 
added. 700 µL of PEG (50% Peg 4000 in LA) was added and mixed thoroughly by micropipetting. 
The solution was then incubated in a water bath at 30°C for 30 minutes and then 42°C for 15 
minutes. These cells were centrifuged at 13200 RPM for 3 minutes and the supernatant was 
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discarded. The pellet was resuspended in 300 µL TE pH 7.5 and different volumes of the solution 
was plated on U⁻H⁻ Glucose plates. These plates were incubated for 2-3 days at 30°C.  
Yeast SDS-PAGE and Western Blot 
Single colonies of yeast were grown shaking overnight at 30°C in 2 mL of U⁻H⁻W glucose 
media. The following day, this suspension was centrifuged at 13200 RPM for 3 minutes at room 
temperature and the resulting supernatant was discarded. These cells were then washed with 1 mL 
of U⁻H⁻W⁻ galactose/raffinose media, and centrifuged at 13200 RPM for 3 minutes once again 
with the supernatant discarded. This pellet was resuspended in 500 µL of U⁻H⁻W⁻ 
galactose/raffinose media. This solution was transferred to test tubes to which 500 µl U⁻H⁻ 
galactose/raffinose media had already been added. These cells were incubated while rotating for 4 
hours at 30°C. At the end of the incubation period, the cells were transferred to microcentrifuge 
tubes and boiled for 3 minutes. 0.1 g of 0.2 mm glass beads were added to the cells, which were 
vortexed for 2 minutes. 70 µl of EBS (2% SDS, 80 mM Tris pH 6.8, 10% glycerol, 1.5% DTT, 
and 0.1 mg/ml bromophenol blue) was added to the cells and the samples were boiled for 1 minute 
and centrifuged for 1 minute at 13200 RPM. The supernatant was analyzed using SDS-PAGE with 
a 12% resolving gel and 5% stacking gel, and a Western transfer was performed with a PVDF 
membrane. α-LexA-HRP was used as the primary antibody for the bait fusion protein. This 
allowed for confirmation that the fusion protein was expressed and stable.  
High Efficiency Yeast Transformation 
An individual colony of EGY48 yeast containing pSH18-34 as well as LexA-Omi31-133 in 
pGilda was grown overnight at 30 °C while shaking in 50 ml of U-H- glucose medium. This 
culture was diluted the following day to 300 mL with U-H- glucose medium and grown to an 
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OD600nm of 0.9. The cells were then harvested by centrifugation at 3800 RPM for 5 minutes, and 
the resulting supernatant was discarded. The cells were washed with 20 mL of sterile water and 
centrifuged for another 5 minutes at 3800 RPM with the supernatant discarded. The solutions 
were resuspended in 20 mL LA (0.1M LiOAc in TE) and spun again for 5 minutes at 3800 RPM. 
This pellet was resuspended in 5 mL of LA. 100 µl of competent yeast was aliquoted into 1.5 mL 
microcentrifuge tubes.10 μg DNA (HeLa cDNA library in pJG4-5), 100 μg of denatured salmon 
sperm DNA, and 600 μl of 40% PEG was added to the aliquots. The mixtures were resuspended 
until homogeneous. The transformation reaction was then incubated at 30°C for 30 minutes and 
then heat shocked at 42°C for 15 minutes. The samples were centrifuged and the supernatant was 
aspirated. The pellet was resuspended in 500 μL of sterile water. 300 μL of this solution of yeast 
was plated on 24 x 24 cm U⁻H⁻W⁻ galactose/raffinose plates and incubated at 30°C for 2-3 days.  
Screening of Library 
The yeast were grown on U⁻H⁻W⁻L⁻ galactose/raffinose plates for growth selection, and 
positive colonies were plated onto a U⁻H⁻W⁻ glucose plate. This plate was incubated at 30°C for 
2-3 days. These colonies were then streaked onto U⁻H⁻W⁻ glucose/X-Gal and U⁻H⁻W⁻ 
galactose/raffinose/X-Gal plates. Blue colonies on these plates indicated a positive interaction. 
Release of Plasmid from Yeast 
Positive colonies were selected to perform a release the pJG4-5 plasmid with the HeLa 
cDNA library insert. These colonies were grown rotating at 30°C overnight in 1 mL of W⁻ glucose 
media. The following day, 800 µL of yeast was transferred to in a microcentrifuge screw-lid tubes 
and spun for 1 minute at 13200 RPM. The supernatant was aspirated and the pellet was 
resuspended in 200 µL of yeast lysis solution (2% TritonX-100, 1% SDS, 100 mM NaCl, 10 mM 
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Tris pH 8.0, 1 mM EDTA). 0.3 g of 150 µm glass beads and 200 µL of phenol-cloroform-ioamyl 
alcohol was added to the solution.  The tubes were vortexed vigorously using a mini-beadbeater 
for 2 minutes. They were then centrifuged for 5 minutes at 13,200 RPM until three distinct layers 
were observed within the tube. The top layer contained the DNA of interest while the middle layer 
contained protein and the bottom layer contained cellular debris. Hence, the top layer was kept and 
a DNA precipitation procedure was performed.   
KC8 Transformation 
The plasmids were transformed into bacterial KC8 cells using electroporation. This 
solution was plated onto WM9 AMP plates and incubated overnight at 37oC. A single colony was 
selected from each plate and grown in LB AMP media overnight.  
Retransformation 
The boiling method was used to obtain the plasmid DNA from the KC8 cells. This was 
transformed back into yeast cells containing the pSH18-34 plasmid and the pGilda vector carrying 
the bait. These samples were plated onto U⁻H⁻W⁻ glucose plates. Colonies growing on these plates 
were subsequently grown on U-H-W- Glucose/XGal plates and U-H-W- Galactose/Raffinose/X-Gal 
plates for color selection. A colony that was blue on the U-H-W- Galactose/Raffinose/X-Gal plates 
and white on the U-H-W- Glucose/XGal was deemed a true positive interactor. 
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CHAPTER 3: RESULTS 
Previous data on the N-terminal Domain of Omi 
 Previous experiments performed in the Zervos lab indicated the potential function of the 
N-terminal domain of Omi in promoting apoptosis under conditions of mitochondrial stress. 
Various constructs were created including a full length Omi and different portions of the N-
terminal domain with amino acids 1-45 (includes the mitochondrial targeting signal and a few 
additional amino acids), amino acids 1-88 (includes the mitochondrial targeting signal and all three 
PRAAXXTXXP motifs), and amino acids 1-133 (includes the entire N-terminal domain that is 
cleaved off to form the mature protein, stopping just short of the AVPS motif) (Figure 7). The 
constructs were expressed as fusions to the green fluorescent protein (GFP).  
 These constructs were transfected into LLC-PK1 cells (pig proximal tubule epithelial cells) 
and treated with antimycin (1 M) for 24 hours. Antimycin acts as an inhibitor of cellular 
respiration by disrupting the electron transport chain and therefore prevents the production of ATP 
through oxidative phosphorylation. In addition, it causes the creation of toxic free radicals harmful 
to the cell. As a result, antimycin was used in this experiment to induce mitochondrial stress. 
Apoptosis was monitored using flow cytometry with AnnexinV staining. AnnexinV binds 
phosphatidylserine, and the presence of this molecule on the outer membrane of cells serves as an 
indicator of apoptosis. Apoptosis data was acquired for a population of 10,000 GFP transfected 
cells.  
 For all constructs, cells showed greater levels of apoptosis under conditions of stress 
compared to untreated cells. Cells possessing full length Omi showed the greatest level of 
apoptosis followed by the cells containing the full N-terminal domain. Cells containing Omi1-133 
 27 
showed significantly higher levels of apoptosis than cells transfected with a truncated N-terminal 
domain, suggesting that the N-terminal domain of Omi most likely plays a role in promoting 
apoptosis, although the mechanism through which this occurs is unclear (Figure 8). 
 These preliminary results served as the impetus for this project. It suggested that the N-
terminal domain has a function within the cell, possibly related to apoptosis. Identifying interactors 
of this N-terminal domain could potentially give clues as to the specific function of the N-terminal 






















Figure 7. Omi constructs 
A full length Omi includes a mitochondrial targeting signal, AVPS motif, catalytic domain containing the catalytic 
triad of residues, and a C-terminal PDZ domain. Various constructs containing different lengths of the N-terminal 












Figure 8. Flow cytometry to monitor apoptosis with different Omi constructs 
LLC-PK1 cells (pig proximal tubule epithelial cells) were transfected with the various Omi constructs and treated with 
antimycin to induce mitochondrial stress (1 micromole for 24 hours). Flow cytometry with AnnexinV staining was 








Expression and Stability of the Bait 
 The DNA fragment corresponding to Omi’s N-terminal domain aa 31-133 was cloned into 
the pGilda vector, and the expression and stability of the bait in yeast was tested. Yeast were 
transformed with the LexA-Omi31-133 plasmid and plated on U
-H- plates. These plates were allowed 
to incubate for several days at 30oC. Single colonies were picked from these plates and grown 
overnight in U-H- media. These yeast were induced the following day with U-H- galactose/raffinose 
media and lysed. Uninduced (control) yeast were grown in U-H- glucose media. SDS PAGE and a 
Western blot analysis with LexA specific antibodies was used to verify that the LexA-Omi31-133 
bait was both expressed and stable within the yeast (Figure 9). Omi31-133 is roughly 10.5 kDa and 
LexA is 24 kDa. Thus, it was expected that the LexA-Omi31-133 would be 34.5 kDa. The Western 
blot shows no bands for the uninduced samples, since glucose represses the GAL1 promoter in 
pGilda. Conversely, galactose/raffinose promotes expression with a GAL1 promoter, so yeast in 
the induced condition expressed LexA or LexA-Omi31-133, showing bands at 24 kDa and 34.5 kDa, 













Figure 9. Expression and stability of LexA-Omi31-133 in yeast 
The LexA-Omi31-133 protein is 34.5 kDa, and the LexA protein alone is 24 kDa. Yeast transfected with the empty 
pGilda vector or the fusion bait LexA-Omi1-133 were grown in U-H- galactose/raffinose media (induced) or U-H- 
glucose media (uninduced). Yeast extracts were separated by SDS-PAGE and analyzed by Western blotting using 








Screen of HeLa cDNA library 
The H2Y screen was used to isolate interactors against the LexA-Omi31-133 bait as described 
in the Methods section. Several yeast colonies appeared that could potentially contain a specific 
interactor. The plasmid from these colonies was isolated and sequenced. DNA sequencing revealed 
the cDNA represents a partial length sequence for Rab2A, encoding amino acids 7-212 (Figure 
10). PCR and specific primers were used to amplify a full length cDNA clone for the human Rab2A 
protein (Table 2). This was then cloned back to the pJG-4-5 vector and used to transform yeast. 























Table 2. Primer Sequences for Full Length Rab2A 
Primer  Sequence (5  3) Restriction Site 
Forward GGCGAATTCATGGCGTACGCCTATCTCTTC  EcoRI 
Reverse CCGCTCGAGTCAACAGCAGCCGCCCCC  XhoI 
 
These forward and reverse primers were used to create a full length clone for Rab2A with an EcoRI restriction site 















Figure 10. cDNA clone representing the Rab2A polypeptide is a specific interactor of LexA-Omi31-133.  
DNA and corresponding amino acid sequence of the partial clone representing part of the Rab2A 
protein that was isolated as a specific interactor in our yeast two-hybrid screen (blue). The DNA 













Figure 11. Full length Rab2A interacts specifically with LexA-Omi31-133 in yeast 
The cDNA library screen originally identified a partial length sequence of Rab2A as an interactor of Omi21-133. A full 
length clone of Rab2A was produced, cloned back to the pJG-4-5 vector, and used to transform yeast. The 
characteristic blue color produced in the presence of X-Gal indicating expression of the reporter system confirms that 







CHAPTER 4: DISCUSSION 
Omi/HtrA2 was first identified as a mammalian homolog to the bacterial heat shock protein 
HtrA, and since its discovery, multiple studies have implicated this mitochondrial protease in the 
quality control of mitochondrial proteins, mitochondrial dynamics, autophagy, as well as apoptosis 
[2, 17, 24, 28, 38]. It has been assumed that all properties assigned to Omi are entirely mediated 
by its ability to function as a serine protease and degrade specific substrates. Some of these 
substrates have already been identified and represent a diverse group of both mitochondrial and 
cytoplasmic proteins. A paradox in the biological function of Omi is the presence of a very large 
N-terminal domain in the precursor Omi protein that is cleaved and remove to create the functional 
active protease. The normal function of this large N-terminal domain is unknown. It is assumed to 
be a mitochondrial targeting sequence, which does not help to explain its size or the various 
structural characteristics that it contains. We hypothesized that the amino terminal of Omi after it 
is removed from the precursor protein is stable and has a distinct function. In this work, we tried 
to identify the potential function of Omi’s N-terminus by isolating and characterizing its specific 
interactors. This method has been used successfully in the past to define the function of a protein 
through its interactions. In addition, it provides information as to the potential stability of the N-
terminus when expressed in yeast. 
We performed a yeast two-hybrid screen, using the N-terminal domain of Omi (amino 
acids 31-133). Omi 1-30 amino acids represent the mitochondrial targeting sequence and were not 
included, as the success of the yeast two-hybrid relies on an interaction that occurs within the 
nucleus. The expression and stability of the LexA-Omi31-133 suggested the Omi31-133 polypeptide 
can be expressed and is stable in yeast cells. The yeast two-hybrid screen of a HeLa cDNA library 
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revealed a novel interactor, the Rab2A protein. Rab2A was able to specifically and strongly 
interact with the LexA-Omi31-133.  
The Rab (Ras-related in the brain) GTPases comprise a family of proteins within the Ras 
superfamily that are found within all eukaryotic organisms. Localized on the cytosolic side of 
intracellular membranes, Rab GTPases are essential for coordinating vesicle traffic within the cell 
through interactions with specific effector molecules such as tethering factors, kinases, and 
phosphatases [34, 36]. Rab has been shown to influence numerous aspects of trafficking including 
vesicle uncoating, budding, motility, fusion, and receptor signaling as well as play key roles in 
cellular signaling [34].  
Rab GTPase activation is controlled by the antagonistic effects of GDP/GTP exchange 
factors (GEFs) and RAB GTPase activating proteins (GAPs). Rab alternates between two states: 
active Rab is bound to GTP while inactive Rab is bound to GDP. GEFs catalyze the conversion of 
GDP for GTP to form the active protein, and GAPs produce the opposite effect by promoting GTP 
hydrolysis to GDP [35]. With over 60 members of Rab proteins in the human genome, many Rab 
proteins have been shown to be the result of gene duplication events and have high sequence 
identity to one another. Even between eukaryotes, Rab function is highly conserved; yeast lacking 
a Rab enzyme can effectively use a mammalian homolog [34]. 
The Rab GTPase identified as an interactor of Omi, Rab2A, is suggested to be a key player 
in the process of autophagy and endocytosis. Rab2A was discovered to be a binding partner of a 
tethering complex known as HOPS (homotypic fusion and vacuole protein sorting), which is 
responsible for degradation of autophagosomes and endosomes. Combined with previous 
knowledge of Rab7’s interaction with HOPS, a model was proposed through which Rab2A works 
 38 
in conjunction with Rab7 in order to promote fusion of autophagosomes and endosomes with 
lysosomes. Rab2A knockdown or siRNA treatment resulted in accumulation of autophagic 
vesicles within the cell [37]. Previous research has revealed that Omi activates autophagy (more 
specifically mitophagy) by regulating the E3 ubiquitin ligase Mulan [38]. Thus, Rab2A’s role in 
autophagy is of interest because it could describe another pathway through which Omi regulates 
autophagy within the cell. The potential link between Omi and Rab2A in autophagy has clinical 
significance since autophagy degrades pathogenic protein aggregates whose build up has been 
implicated in neurodegenerative diseases [38].  
Further experimentation needs to be completed to confirm that this interaction between 
Rab2A and Omi occurs in mammalian cells under physiological conditions. If a specific antibody 
against the N-terminus of Omi can be created, experiments can be done to determine the 
subcellular localization of this domain (mitochondrial versus cytoplasmic). In addition, a specific 
antibody could be used to monitor the expression and stability of the amino terminal domain and 
its potential trafficking to the lysosomes during autophagy. Finally, whether the amino terminal 
domain of Omi is involved in the pathological conditions where the protease has been implicated 
needs further investigation. It is expected that the amino terminal domain of Omi is created through 
auto-degradation. As such, mutations that affect the protease activity of Omi will block the release 
of the amino terminal domain from the precursor protein. This could prove detrimental to cells by 
affecting several biological processes including autophagy. Thus, elucidation of the role of the N-




1. Gray, C. W., Ward, R. V., Karran, E., Turconi, S., Rowles, A., Viglienghi, D., ... & 
Savopoulos, J. (2000). Characterization of human HtrA2, a novel serine protease involved in 
the mammalian cellular stress response. European Journal of Biochemistry, 267(18), 5699-
5710. http://dx.doi.org/10.1046/j.1432-1327.2000.01589.x 
 
2. Faccio, L., Fusco, C., Chen, A., Martinotti, S., Bonventre, J. V., & Zervos, A.S. (2000). 
Characterization of a novel human serine protease that has extensive homology to bacterial 
heat shock endoprotease HtrA and is regulated by kidney ischmia. Journal of Biological 
Chemistry, 275(4), 2581-2588. http://dx.doi.org/10.1074/jbc.275.4.2581  
 
3. Hegde, R., Srinivasula, S. M., Zhang, Z., Wassell, R., Mukattash, R., Cilenti, L., ... & 
Alnemri, E. S. (2002). Identification of Omi/HtrA2 as a mitochondrial apoptotic serine 
protease that disrupts inhibitor of apoptosis protein-caspase interaction. Journal of Biological 
Chemistry, 277(1), 432-438. http://dx.doi.org/10.1074/jbc.M109721200 
 
4. Kadomatsu, T., Mori, M., & Terada, K. (2007). Mitochondrial import of Omi: the definitive 
role of the putative transmembrane region and multiple processing sites in the amino-
terminal segment. Biochemical and biophysical research communications, 361(2), 516-521. 
http://dx.doi.org/10.1016/j.bbrc.2007.07.053  
 
5. Cilenti, L., Ambivero, C. T., Ward, N., Alnemri, E. S., Germain, D., & Zervos, A. S. (2014). 
Inactivation of Omi/Htra2 protease leads to deregulation of mitochondrial Mulan E3 
ubiquitin ligase and increased mitophagy. Biochimica et Biophysica Acta: Molecular Cell 
Research, 1843(7), 1295-1307. http://dx.doi.org/10.1016/j.bbamcr.2014.03.027  
 
6. Kang, S., Fernandes-Alnemri, T., & Alnemri, E. S. (2013). A novel role for the 
mitochondrial HTRA2/OMI protease in aging. Autophagy, 9(3), 420-421. 
http://dx.doi.org/10.4161/auto.22920 
 
7. Jones, J. M., Datta, P., Srinivasula, S. M., Ji, W., Gupta, S., Zhang, Z., . . . Meisler, M. H. 
(2003). Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of 
mnd2 mutant mice. Nature, 425, 721-727. http://dx.doi.org/10.1038/nature02052  
 
8. Plun-Favreau, H., Klupsch, K., Moisoi, N., Gandhi, S., Kjaer, S., Frith, D., ... & Wood, N. 
W. (2007). The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated 
kinase PINK1. Nature cell biology, 9(11), 1243-1252. http://dx.doi.org/10.1038/ncb1644 
 
9. Strauss, K. M., Martins, L. M., Plun-Favreau, H., Marx, F. P., Kautzmann, S., Berg, D., ... & 
Wolburg, H. (2005). Loss of function mutations in the gene encoding Omi/HtrA2 in 




10. Simón-Sánchez, J., & Singleton, A. B. (2008). Sequencing analysis of OMI/HTRA2 shows 
previously reported pathogenic mutations in neurologically normal controls. Human 
molecular genetics, 17(13), 1988-1993. http://dx.doi.org/10.1093/hmg/ddn096  
 
11. Park, H.-J., Kim, S.-S., Seong, Y.-M., Kim, K.-H., Goo, H. G., Yoon, E. J., . . . Rhim, H. 
(2006). β-amyloid precursor protein is a direct cleavage target of HtrA2 serine protease. The 
Journal of Biological Chemistry, 281, 34277-34287. 
http://dx.doi.org/0.1074/jbc.M603443200  
 
12. Inagaki, R., Tagawa, K., Qi, M.-L., Enokido, Y., Ito, H., Tamura, T., . . . Okazawa, H. 
(2008). Omi/HtrA2 is relevant to the selective vulnerability of striatal neurons in 
Huntington’s disease. European Journal of Neuroscience, 28(1), 30-40. 
http://dx.doi.org/0.1111/j.1460-9568.2008.06323.x  
 
13. Lee, S., Lee, J., Kim, H., Kim, S., & Yoo, N. (2003). Immunohistochemical analysis of 
Omi/HtrA2 expression in stomach cancer. APMIS, 111(5), 586-590. 
http://dx.doi.org/10.1034/j.1600-0463.2003.1110508.x  
 
14. Yang, X., Xing, H., Gao, Q., Chen, G., Lu, Y., Wang, S., & Ma, D. (2005). Regulation of 
HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian 
cancer cells. Gynecologic Oncology, 97(2), 413-421. 
http://dx.doi.org/10.1016/j.ygyno.2004.12.055  
 
15. Hu, X., Xu, Y., Chen, X., Ping, H., Chen, Z., & Zeng, F. (2006). Immunohistochemical 
analysis of Omi/HtrA2 expression in prostate cancer and benign prostatic hyperplasia. 
APMIS, 114(12), 893-898. http://dx.doi.org/10.1111/j.1600-0463.2006.apm_271.x  
 
16. Li, W., Srinivasula, S. M., Chai, J., Li, P., Wu, J. W., Zhang, Z., ... & Shi, Y. (2002). 
Structural insights into the pro-apoptotic function of mitochondrial serine protease 
HtrA2/Omi. Nature Structural & Molecular Biology, 9(6), 436-441. 
http://dx.doi.org/10.1038/nsb795  
 
17. Suzuki, Y., Imai, Y., Nakayama, H., Takahashi, K., Takio, K., & Takahashi, R. (2001). A 
serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing 
cell death. Molecular cell, 8(3), 613-621. http://dx.doi.org/10.1016/S1097-2765(01)00341-0 
 
18. Kadomatsu, T., Mori, M., & Terada, K. (2007). Mitochondrial import of Omi: the definitive 
role of the putative transmembrane region and multiple processing sites in the amino-
terminal segment. Biochemical and biophysical research communications, 361(2), 516-521. 
http://dx.doi.org/10.1016/j.bbrc.2007.07.053  
 
19. Verhagen, A. M., Silke, J., Ekert, P. G., Pakusch, M., Kaufmann, H., Connolly, L. M., ... & 
Moritz, R. L. (2002). HtrA2 promotes cell death through its serine protease activity and its 
ability to antagonize inhibitor of apoptosis proteins. Journal of Biological Chemistry, 277(1), 
 41 
445-454. http://dx.doi.org/10.1074/jbc.M109891200  
 
20. Hegde, R., Srinivasula, S. M., Zhang, Z., Wassell, R., Mukattash, R., Cilenti, L., ... & 
Alnemri, E. S. (2002). Identification of Omi/HtrA2 as a mitochondrial apoptotic serine 
protease that disrupts inhibitor of apoptosis protein-caspase interaction. Journal of Biological 
Chemistry, 277(1), 432-438. http://dx.doi.org/10.1074/jbc.M109721200 
 
21. Cilenti, L., Soundarapandian, M. M., Kyriazis, G. A., Stratico, V., Singh, S., Gupta, S., ... & 
Zervos, A. S. (2004). Regulation of HAX-1 anti-apoptotic protein by Omi/HtrA2 protease 
during cell death. Journal of Biological Chemistry, 279(48), 50295-50301. 
http://dx.doi.org/10.1074/jbc.M406006200  
 
22. Trencia, A., Fiory, F., Maitan, M. A., Vito, P., Barbagallo, A. P. M., Perfetti, A., ... & 
Formisano, P. (2004). Omi/HtrA2 promotes cell death by binding and degrading the anti-
apoptotic protein ped/pea-15. Journal of Biological Chemistry, 279(45), 46566-46572. 
http://dx.doi.org/ 10.1074/jbc.M406317200 
 
23. Cilenti, L., Lee, Y., Hess, S., Srinivasula, S., Park, K. M., Junqueira, D., . .. Zervos, A. S. 
(2003). Characterization of a novel and specific inhibitor for the pro-apoptotic protease 
Omi/HtrA2. The Journal of Biological Chemistry, 278(13), 11489-11494. 
http://dx.doi.org/10.1074/jbc.M212819200  
 
24. Radke, S., Chander, H., Schäfer, P., Meiss, G., Krüger, R., Schulz, J. B., & Germain, D. 
(2008). Mitochondrial protein quality control by the proteasome involves ubiquitination and 
the protease Omi. Journal of Biological Chemistry, 283(19), 12681-12685. 
http://dx.doi.org/10.1074/jbc.C800036200 
 
25. Liu, M. J., Liu, M. L., Shen, Y. F., Kim, J. M., Lee, B. H., Lee, Y. S., & Hong, S. T. (2007). 
Transgenic mice with neuron-specific overexpression of HtrA2/Omi suggest a 
neuroprotective role for HtrA2/Omi. Biochemical and biophysical research communications, 
362(2), 295-300. http://dx.doi.org/10.1016/j.bbrc.2007.07.118 
 
26. Tang, A., Downward, J., & Iaccarino, I. (n.d). The serine protease Omi/HtrA2 regulates 
apoptosis by binding XIAP through a reaper-like motif. Journal Of Biological 
Chemistry, 277(1), 439-444. 
 
27. Nuytemans, K., Rousseau, F., Theuns, J., Schymkowitz, J., Van Broeckhoven, C., Bogaerts, 
V., & ... Pickut, B. (n.d). Genetic variability in the mitochondrial serine protease HTRA2 
contributes to risk for Parkinson disease. Human Mutation, 29(6), 832-840. 
 
28. Goo, H., Rhim, H., & Kang, S. (2014). Research Article: HtrA2/Omi influences the stability 
of LON protease 1 and prohibitin, proteins involved in mitochondrial 
homeostasis. Experimental Cell Research, 328(Cell polarity), 456-465. 
doi:10.1016/j.yexcr.2014.07.032 
 42 
29. Nam, M., Seong, Y., Park, H., Choi, J., Kang, S., & Rhim, H. (2006). The homotrimeric 
structure of HtrA2 is indispensable for executing its serine protease activity. Experimental 
And Molecular Medicine, 38(1), 36. 
 
30. Mandel, H., Saita, S., Edvardson, S., Jalas, C., Shaag, A., Goldsher, D., & ... Elpeleg, O. 
(2016). Deficiency of HTRA2/Omi is associated with infantile neurodegeneration and 3-
methylglutaconic aciduria. Journal of Medical Genetics, (10). 690. 
 
31. Olahova, M., Thompson, K., Hardy, S. A., Barbosa, I. A., Besse, A., Anagnostou, M., & ... 
Taylor, R. W. (2017). Pathogenic variants in HTRA2 cause an early-onset mitochondrial 
syndrome associated with 3-methylglutaconic aciduria. Journal Of Inherited Metabolic 
Disease, (1), 121. doi:10.1007/s10545-016-9977-2 
 
32. Dudek, J., Rehling, P., & van der Laan, M. (2013). Review: Mitochondrial protein import: 
Common principles and physiological networks. BBA - Molecular Cell 
Research, 1833(Protein Import and Quality Control in Mitochondria and Plastids), 274-285. 
doi:10.1016/j.bbamcr.2012.05.028 
 
33. Calvo, S. E., Julien, O., Clauser, K. R., Shen, H., Kamer, K. J., Wells, J. A., & Mootha, V. K. 
(2017). Comparative Analysis of Mitochondrial N-Termini from Mouse, Human, and 
Yeast. Molecular & Cellular Proteomics: MCP, 16(4), 512-523. 
doi:10.1074/mcp.M116.063818 
 
34. Stenmark, H. (2009). Rab GTPases as coordinators of vesicle traffic. Nature Reviews 
Molecular Cell Biology, (8), 513. 
 
35. Stenmark, H., & Olkkonen, V. M. (2001). The Rab GTPase family. Genome Biology, 2(5), 
3007.1–3007.7. https://doi.org/10.1186/gb-2001-2-5-reviews3007 
 
36. Dikic, I., Kern, A., Behl, C., & Dikic, I. (n.d). The integration of autophagy and cellular 
trafficking pathways via RAB GAPs. Autophagy, 11(12), 2393-2397. 
 
37. Lorincz, P., Toth, S., Benko, P., Lakatos, Z., Boda, A., Glatz, G., & ... Juhasz, G. (2017). 
Rab2 promotes autophagic and endocytic lysosomal degradation. The Journal Of Cell 
Biology, (7), 1937. doi:10.1083/jcb.201611027 
 
38. Li, B., Hu, Q., Wang, H., Man, N., Ren, H., Wen, L., & ... Wang, G. (2010). Omi/HtrA2 is a 
positive regulator of autophagy that facilitates the degradation of mutant proteins involved in 
neurodegenerative diseases. Cell Death & Differentiation, 17(11), 1773-1784. 
doi:10.1038/cdd.2010.55 
 
39. Goo, H., Rhim, H., & Kang, S. (2017). Pathogenic Role of Serine Protease HtrA2/Omi in 




40. Bras, M., Queenan, B., & Susin, S. (2005). Programmed cell death via mitochondria: 
Different modes of dying. Biochemistry (00062979), 70(2), 231-239. doi:10.1007/s10541-
005-0105-4 
 
41. Rathke-Hartlieb, S., Schlomann, U., Heimann, P., Meisler, M. H., Jockusch, H., & Bartsch, J. 
W. (2002). Regular Article: Progressive Loss of Striatal Neurons Causes Motor Dysfunction 
in MND2 Mutant Mice and Is Not Prevented by Bcl-2. Experimental Neurology, 17587-97. 
doi:10.1006/exnr.2002.7868 
 
42. Dudek, J., Rehling, P., & van der Laan, M. (2013). Review: Mitochondrial protein import: 
Common principles and physiological networks. BBA - Molecular Cell 
Research, 1833(Protein Import and Quality Control in Mitochondria and Plastids), 274-285. 
doi:10.1016/j.bbamcr.2012.05.028 
 
43. Seong, Y., Park, H., Seong, G., Choi, J., Yoon, S. K., Min, B., & ... Rhim, H. (2004). N-
terminal truncation circumvents proteolytic degradation of the human HtrA2/Omi serine 
protease in Escherichia coli: rapid purification of a proteolytically active HtrA2/Omi. Protein 
Expression And Purification, 33200-208. doi:10.1016/j.pep.2003.10.002 
